• Medicus shifted SkinJect development to focus exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions.
• Internally sponsored development in sporadic or nodular basal cell carcinoma will be concluded under a capital-efficient portfolio strategy.
• Clinical plan centers on FDA-authorized SKNJCT-005, an NDA-enabling Phase 2b study in Gorlin syndrome.
• Regulatory work will continue with FDA’s orphan office to support orphan-related requests, with additional information to be submitted.
• Independent commercial modeling tied to the rare-disease strategy assumed net pricing near $25,800 per treatment, a $1.1 billion U.S. market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609210730PRIMZONEFULLFEED9830185) on September 21, 2026, and is solely responsible for the information contained therein.